Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Expression cloning and antigenic analysis of the nucleocapsid protein of equine arteritis virus

E.D. Chirnside *, P.M. Francis, J.A. Mumford

Centre for Preventive Medicine, The Animal Health Trust, Lanwades Park, Kennett, Newmarket, Suffolk, CB8 7PN, UK

Accepted 12 September 1995

Abstract

A series of recombinant fusion proteins derived from equine arteritis virus (EAV) open reading frame (ORF) 7 have been used to define the immunoreactive region of the viral nucleocapsid (N) protein. Reactivities of recombinant N fusion proteins with post-infection equine sera in immunoblots and ELISAs indicate that the major nucleocapsid protein epitope is located within amino acid residues 1–69. In ELISAs two recombinant nucleocapsid fusion proteins containing residues 1–69 (rN1–69) and 1–28 (rN1–28) discriminated between pre- and post-infection, and pre- and post-vaccination serum samples. Additionally rN1–69 and rN1–28 detected seroconversions following vaccination with a killed virus preparation, even in the absence of a detectable virus neutralising response. Although a good correlation existed between virus neutralising antibody and rN1–69 ELISA positive values in post-infection sera, all the rN proteins failed to induce any virus neutralising response in immunised rabbits.

Keywords: Arterivirus; Equine arteritis virus (EAV); Nucleocapsid (N) protein; Antigenic analysis; Diagnostic antigen

1. Introduction

Equine viral arteritis (EVA) is a debilitating disease in horses (Chirnside, 1992) which at its most severe can cause abortion (Doll et al., 1957) and foal death (Golnik et al., 1981; Vaala et al., 1992). Diagnosis is complicated because the
symptoms of infection are extremely varied and because disease outbreaks may remain clinically unapparent, only coming to light following serosurveys of equine populations. Virus transmission is by both the venereal and respiratory routes, with between 30 and 60% of seropositive stallions permanently shedding equine arteritis virus (EAV) in their semen following infection (Timoney et al., 1986). Shedding stallions used in breeding have initiated the spread of EVA to mares which, once infected, shed virus in most body fluids during the viraemic phase (McCollum et al., 1961) and may infect in-contacts by the respiratory route.

EAV is a single-stranded, positive-sense RNA virus recently classified in the genus Arterivirus (Cavanagh et al., 1994) which includes lactate dehydrogenase-elevating virus (Kuo et al., 1992; Godeny et al., 1993), simian haemorrhagic fever virus (Plagemann and Moennig, 1992) and the virus causing porcine respiratory and reproductive syndrome (PRRS, Conzelmann et al., 1993; Lelystad virus, Meulenberg et al., 1993a, b). The EAV virion has a diameter of 50–70 nm (Hyllseth, 1973) and consists of an isometric nucleocapsid (35 nm) surrounded by an envelope which carries ring-like surface structures with a diameter of 12–15 nm (Murphy, 1980). The nucleocapsid is composed of an infectious, polyadenylated, single-stranded genomic RNA with a size of 12.7 kb (den Boon et al., 1991) and phosphorylated core protein (N) Mr 12–14K (Hyllseth, 1973; Zeegers et al., 1976). The envelope contains a 16K non-glycosylated protein (M) and N-glycosylated proteins of Mr 25K (Gs) and 30–42K (Gl) (de Vries et al., 1992).

The major viral structural proteins Gl, M and N are encoded by open reading frames (ORFs) 5, 6 and 7, respectively; the minor envelope glycoprotein Gs is specified by ORF 2 (de Vries et al., 1992). ORFs 3 and 4 are both predicted to encode N-glycosylated membrane proteins (den Boon et al., 1991); however, the products of these ORFs have not been characterised. Virus neutralising monoclonal antibodies are directed at Gl (Balasuriya et al., 1993, 1995; Deregt et al., 1994) and recombinant Gl is currently under investigation as a subunit vaccine (Chirnside et al., 1995a) and as a diagnostic test antigen (Chirnside et al., 1995b). Should Gl prove useful as a subunit vaccine antigen, a serodiagnostic test based on an alternative virus antigen could allow differential discrimination of subunit vaccinated from other seropositive horses. This would aid the identification of naturally infected seropositive animals, in particular stallions likely to be shedding EAV in their semen, and could consequently reduce the risk of virus transmission by the venereal route.

Alternative protein candidates for use as diagnostic antigens include the EAV structural proteins Gs, M and N. EAV Gs comprises ≤ 2% of the virion protein, has a complex glycosylation structure, and is unlikely to be a major viral antigen (de Vries et al., 1992, 1995; de Vries, 1994). Analysis of the M protein indicates that it is very hydrophobic and most likely submerged within the virus particle (de Vries et al., 1992). N comprises 35–40% of the total virion protein and is not notably hydrophobic. Fusion proteins based on EAV Gs and N react in ELISA with virus neutralising equine sera (Chirnside et al., 1995a) and rabbit, hamster and equine antisera recognise EAV N, M, Gl, and Gs in immunoprecipitations and immunoblots (van Berlo et al., 1986; Iwashita and Harasawa, 1987; de Vries et
In this paper we present the results of cloning fragments of the EAV N protein into the bacterial expression vector pGEX to produce recombinant glutathione-S-transferase fusion proteins, and investigate their reactivity to equine sera in Western blots and ELISA.

2. Materials and methods

2.1. Materials

Restriction enzymes, deoxynucleoside triphosphate solutions, glutathione Sepharose 4B and pGEX-2T and -3X expression vectors were obtained from Pharmacia. Calf intestinal alkaline phosphatase, lysozyme, the Klenow large fragment of DNA polymerase, DNase I, T4 DNA polymerase and T4 DNA ligase were supplied by Boehringer Mannheim. Sequenase (Version 2.0) was obtained from U.S. Biochemical and biotin-labelled affinity-purified goat antiserum to horse IgG and streptavidin peroxidase conjugate were from Kirkegaard and Perry Laboratories Inc.

2.2. Plasmid constructs

Plasmid DNA manipulations were performed by standard methods (Sambrook et al., 1989). The prokaryotic expression vectors pGEX-2T and -3X direct the expression of cloned DNA as glutathione-S-transferase (GST) fusion proteins.
under the control of an isopropyl-β-d-thiogalactopyranoside (IPTG)-inducible tac promoter (Smith and Johnson, 1988). EAV cDNA sequences encoding ORF 7 originating from cDNA clone 106 (de Vries et al., 1990) were ligated in frame into pGEX-3X or -2T (Table 1), transformed into *Escherichia coli* strain TG1 (Gibson, 1984), and recombinants selected on Luria broth (LB) agar containing 100 μg ampicillin per ml.

2.3. Screening for fusion proteins

Overnight cultures were diluted twenty-fold in fresh medium, grown for 2 h at 37°C and protein expression induced by addition of IPTG to 0.2 mM. After 5 h growth, 1 ml of culture was centrifuged and the bacterial pellet dissolved in 100 μl sample buffer, incubated for 5 min at 96°C and 10 μl analysed in a sodium dodecyl sulphate (SDS)–12.5% polyacrylamide gel (PAA) which was stained with Coomassie brilliant blue to visualise separated proteins. Double-stranded DNA from clones expressing an altered GST fusion protein was subjected to restriction endonuclease analysis, and recombinant plasmids sequenced with Sequenase to confirm the GST/EAV DNA junction in the correct reading frame. Sequencing was performed using the primer 5'-GGCGACCATCTCCAAA-3' located approximately 40 bp upstream of the pGEX multiple cloning site in addition to internal EAV-specific primers.

2.4. Purification of fusion proteins

Fusion proteins were affinity-purified using glutathione-Sepharose 4B as reported previously (Chirnside et al., 1995a).

2.5. ELISA

Optimal concentrations of reactants were determined by chequerboard titration. Immulon 3 microtitre plates (Dynatech) were coated with 0.5 μg per well of the GST or GST/EAV fusion protein and ELISAs were performed as described previously (Chirnside et al., 1995b). Equine sera at a 10^{-2} dilution had a variable background absorbance (0–0.5) caused by non-specific binding of sera to GST. Consequently the reactivity of each serum sample to GST was subtracted from that of the GST/EAV fusion protein to derive the EAV-specific absorbance value. Test sera were assayed in duplicate against each antigen and the mean absorbance at 490 nm calculated.

2.6. Immunoblotting

Following electrophoretic transfer of proteins from SDS–12.5% polyacrylamide gels onto nitrocellulose membrane immunoblots were performed as described previously (Chirnside et al., 1995b).
2.7. Virus neutralisation (VN) test

The neutralisation titres of equine sera were determined as described by Senne et al. (1985) with minor modifications (Chirnside et al., 1995b).

2.8. Immunisation

New Zealand white rabbits were immunised subcutaneously with 100 μg of affinity-purified GST or GST/EAV fusion protein in Freund’s complete adjuvant, followed 5 weeks later by a second immunisation in Freund’s incomplete adjuvant. Serum was collected at regular intervals and tested by virus neutralisation for antibodies to EAV.

2.9. Antisera

The antisera used in this study were submitted to the Animal Health Trust diagnostic laboratory during 1993. Isolate and vaccine-specific equine sera were kindly provided by Dr. Y. Fukunaga, Japan Racing Association.

3. Results

3.1. Cloning, expression and reactivity of EAV N fusion proteins

The characteristics of nucleocapsid gene fusion proteins and their relationship to each other are given in Table 1. The complete N protein fused to the carboxy terminus of GST was expressed as rN1–110; the remaining N fusion proteins contained smaller regions of the N gene. Although the recombinant proteins were expressed in quantity following IPTG induction (Fig. 1A) and could be purified by affinity gel chromatography on glutathione-Sepharose 4B, the yield of rN1–110 and rN1–69 following purification was reduced compared to rN1–28, rN70–89 and rN90–110. In immunoblots to recombinant N proteins both EAV seropositive and seronegative equine sera recognised GST (Fig. 1B). However only rN1–110 and rN1–69 were strongly bound by post-infection equine sera (Fig. 1B).

In order to examine the reactivities of equine sera in ELISA a panel consisting of 8 seronegative equine sera, used as controls in an EAV G_L ELISA (Chirnside et al., 1995b) were tested against each of the five rN proteins. The mean absorbance of these sera was determined, and a seronegative ELISA cut-off point calculated for each antigen (mean + 2 S.D. for each recombinant protein). In addition, 8 post-infection sera with VN titres ranging from 1.0 to 2.6 were screened to determine their reactivity to each rN antigen. In these ELISAs rN70–89 and rN90–110 failed to react specifically with the post-infection sera (Fig. 2); rN1–110 and rN1–28 reacted with 2 and 4 sera, respectively, whilst rN1–69 reacted with 6/8 of the post-infection equine sera. By comparison, all 8 post-infection sera recognised rG_L55–98 in ELISA.
Fig. 1. (A) Expression of N fusion proteins. Bacterial lysates were run through SDS–12.5% polyacrylamide gels and stained with Coomassie brilliant blue R250. The GST lane contains lysate from pGEX-3X transformed bacteria. GST or rN fusion proteins are indicated by an arrow in each lane. Further details of the rN proteins and their cloning are shown in Table 1. The sizes of marker proteins (Mr) analysed in the same gel are indicated. (B) Immunoblots of purified fusion proteins to a pre- and post-EAV infection serum sample.

Antisera from rabbits immunised with rN1–110, rN1–69 and rN1–28 all recognised GST in ELISA and immunoblots so strongly that EAV-specific reactivity was masked (not shown). Anti-rN sera failed to neutralise EAV in VN tests in contrast to both rabbit and equine anti-rGL55–98 sera which exhibit VN antibody activity (Chirnside et al., 1995a).
Fig. 2. ELISA absorbance values of equine sera to recombinant N proteins. ELISA plates were coated with 0.5 μg per well of purified fusion protein (rN) or GST. The GST absorbance was subtracted from the rN absorbance to derive an EAV-specific value and each bar represents the mean value from two replicates of each serum. The antigen used in ELISA is shown above each graph; the x and y axes show the log_{10} VN titre and ELISA absorbance value, respectively, for the test sera. Cut-off points determining ELISA seropositivity for each antigen, calculated from the absorbance values of 8 VN- control sera (see text), are shown as a horizontal line on each graph: rN1-110 = 0.592; rN1-28 = 0.582; rN1-69 = 0.483; rN70-89 = 0.294; rN90-110 = 0.407; rG L55-98 = 0.100.

3.2. Recombinant N proteins as serodiagnostic antigens

The results of ELISAs with rN1-69 and rN1-28 were compared to results obtained in the EAV VN test and rG L 55-98 ELISA (Chirnside et al., 1995b) using a panel of 47 equine sera. The panel comprised 8 VN- field sera and 8 post-infection samples as internal test controls, sera from 7 horses pre- and two weeks post-vaccination (Artervac, Fort Dodge Laboratories), 2 VN + post-vaccination samples, sera raised to three specific EAV isolates (Bucyrus, 84-KY-A1,
Table 2
Comparison of VN and ELISA tests

| Sera          | VN test Log₁₀ titre * | ELISA test result (A₄₉₀nm) |  |  |  |  |
|---------------|-----------------------|-----------------------------|  |  |  |  |
|               |                       | rG₁₅₅-₉₈ b                  | rN₁-₆₉ c                  | rN₁-₂₈ d |
| Negative controls (n = 8) |                       |                             |                           |          |
| 7             | 0                     | –                           | –                          | –        |
| 1             | 0                     | –                           | –                          | +        |
| Positive controls (n = 8) |                       |                             |                           |          |
| 8             | 1.8-2.7               | +                           | +                          | +        |
| Vaccination samples |                       |                             |                           |          |
|               | pre       | post      | pre       | post      | pre       | post      | pre       | post      |
| 33745         | 0         | 0.3       | 0         | 1.544     | 0.132     | 0.664     | 0.230     | 0.340     |
| 33746         | 0         | 0.45      | 0.111     | 1.886     | 0.353     | 0.967     | 0.344     | 0.580     |
| 33747         | 0         | 0.52      | 0.172     | 3.346     | 0.168     | 2.427     | 0.256     | 1.212     |
| 33962         | 0         | 0         | 0.108     | 2.252     | 0.157     | 0.884     | 0.170     | 0.387     |
| 33963         | 0         | 0.9       | 0.015     | 3.582     | 0.117     | 2.144     | 0.145     | 0.997     |
| 33964         | 0         | 0         | 0.076     | 2.446     | 0.156     | 1.572     | 0.175     | 0.851     |
| 33435         | 0         | 0.3       | 1.774     | 0.348     | 1.452     | 0.286     | 0.491     |
| 35097         | nd        | 1.5       | nd        | 3.242     | nd        | 3.226     | nd        | 2.026     |
| 35098         | nd        | 1.5       | nd        | 3.496     | nd        | 3.441     | nd        | 1.908     |
| Isolate specific sera |       |             |       |             |       |             |       |             |
| Bucyrus       | 3.1       | 3.740      | 3.249     | 1.130     |
| 84-KY-A1      | 2.5       | 1.869      | 0.888     | 0.288     |
| Wroclaw-2     | 2.2       | 1.550      | 0.424     | 0.276     |
| Arvac         | 2.5       | 1.374      | 0.422     | 0.319     |
| Killed Bucyrus| 1.9       | 3.193      | 1.117     | 0.620     |
| Conflicting test results |       |             |       |             |       |             |       |             |
| 31539         | 0         | 2.208      | 0.899     | 0.289     |
| 31571         | 0         | 0.190      | 0.147     | 0.174     |
| 31577         | 0         | 0         | 0.314     | 0.662     |
| 31578         | 0         | 0.170      | 0.215     | 0.315     |
| 31658         | 0         | 1.199      | 0.148     | 0.210     |
| 31724         | 0         | 1.898      | 1.308     | 0.406     |
| 31736         | 0         | 0.222      | 0.101     | 0.148     |
| 31746         | 0         | 0.668      | 0.250     | 0.356     |
| 31568         | 0.9       | 0.071      | 0.163     | 0.140     |
| 31581         | 0.975     | 0.106      | 0.215     | 0.176     |

Boldface represents seropositive results in VN or ELISA test; pre = pre-vaccination serum sample; post = post-vaccination serum sample; nd = not determined.

* Log₁₀ VN antibody titre ≥ 0.6 is deemed seropositive in the EAV VN neutralising test.

b The cut-off value to determine seropositive status was taken as (mean ± 2 S.D.) of the 8 VN negative control sera (positive ≥ 0.085).

c The cut-off value to determine seropositive status was taken as (mean ± 2 S.D.) of the 8 VN negative control sera (positive ≥ 0.177).

d The cut-off value to determine seropositive status was taken as (mean ± 2 S.D.) of the 8 VN negative control sera (positive ≥ 0.308).

Wroclaw-2), to the live virus vaccine (Arvac; an attenuated Bucyrus preparation) and also to a formalin inactivated virus vaccine preparation (Killed Bucyrus). In addition the panel included several field sera which had previously given conflict-
ing results in EAV VN and rG_{1,55–98} ELISA tests in order to confirm their serum antibody status. The results of these ELISAs and VN tests are shown in Table 2. Seropositive cut-off values to each antigen were calculated using 8 VN-field sera (Table 2). All were ELISA – to both rG_{1,55–98} and rN1–69, with only 7 sera ELISA – when tested against rN1–28; serum 32278 had an A_{490 nm} 0.310 which was marginally above the cut-off value (0.308) for this antigen. All eight post-infection, VN + sera were ELISA + to rN1–28, 1–69 and rG_{1,55–98}.

The VN and rG_{1,55–98} ELISA tests gave conflicting results with sera from horses following the administration of one dose of a killed vaccine preparation (Artervac, Fort Dodge Laboratories). Out of 7 paired sera, only one (33963; Table 2) seroconverted in the VN test (titre ≥ 0.6) following vaccination with 3 additional sera having demonstrable VN antibody (0.3–0.52) following vaccination, although not high enough to score as VN +. By comparison, all 7 sets of paired serum samples seroconverted in ELISA to rG_{1,55–98}, rN1–69 and rN1–28 following vaccination. The strongest absorbance changes were seen with rN1–69 and rG_{1,55–98}; the mean absorbance rises following vaccination were 2.335 ± 0.765, 1.240 ± 0.690, and 0.465 ± 0.352 for rG_{1,55–98}, rN1–69 and rN1–28, respectively. Contrary to the results of VN testing, serum 33746 was ELISA + to all three antigens prior to vaccination. The 3 EAV isolate-specific sera and 2 EAV vaccine antisera (Arvac, Killed Bucyrus) neutralised the Bucyrus strain of EAV in VN tests and were ELISA + to both rG_{1,55–98} and rN1–69. However, only the 3 "Bucyrus derived" antisera recognised rN1–28.

The sera which exhibited conflicting rG_{1,55–98} ELISA and VN test results comprised 8 VN – and 2 VN + field sera, none of which were from vaccinated horses. In the VN – group, 4 sera were ELISA + to 2 recombinant antigens derived from different viral proteins. The remaining 4 sera were ELISA + to only one viral protein antigen, either N or G_{1}. Of the 2 VN + sera in this group, 31568 was ELISA – to all 3 recombinant antigens, and 31581 ELISA + to rG_{1,55–98}.

4. Discussion

We have previously demonstrated that following infection, virus neutralising equine sera recognise G_{1} fusion proteins strongly and G_{5} and N fusion proteins inconsistently and poorly (Chirnside et al., 1995a). In the present study the reactivity of a panel of recombinant fusion proteins, comprising complete or small parts of EAV ORF 7, has been used to define the region within amino acids 1–69 as the most immunoreactive region of the viral nucleocapsid protein.

Post infection, seropositive equine sera recognised rN1–110 and rN1–69 in immunoblots and rN1–110, rN1–69 and rN1–28 in ELISA. These constructs contain the amino terminus of N, the loss of which in rN70–89 and rN90–110 produces unreactive proteins in both immunoblots and ELISAs. The poor reactivity of rN1–110 in ELISA could be due to improper folding of the N protein within this construct, as VN sera recognised it fairly strongly in immunoblots. The
complete failure of rN1–28 to react with VN sera in immunoblots, and very poorly in ELISA, may be due, at least in part, to a linear epitope spanning through and beyond amino acid residue 28. In both ELISA and immunoblots the most reactive protein was rN1–69 and although more exhaustive testing is required, these results indicate that the immunoreactive epitope of N is contained within amino acids 1–69 and that the region spanning residue 28 is important for reactivity with equine sera.

The N gene of EAV is highly conserved between isolates (Chirnside et al., 1994) so the failure of specific antisera to the Wroclaw-2 and 84-KY-A1 isolates to react with rN1–28 may be due to differences in the immune response of individual animals rather than to antigenic variation.

The reactivity of both rN1–69 and rG_L 55–98 in ELISA both correlate well with the presence of VN antibody in horse sera. Recent evidence (Balasuriya et al., 1993, 1995; Deregt et al., 1994; Chirnside et al., 1995a, b) indicates that the major neutralising epitope of EAV is located on G_L. Due to its location, protein characteristics and lack of potential glycosylation sites it was unlikely that N would be the target for neutralising antibodies and the failure of N fusion proteins to induce a VN response in rabbits supports this prediction.

On the basis of our comparison to the EAV VN test results rN1–69 and rG_L 55–98 are the antigens of choice for use as serodiagnostic antigens. These ELISA antigens confirmed the presence of EAV-specific antibodies in all the control VN +, post-infection VN + and EAV-specific equine sera tested and were capable of identifying vaccine induced seroconversion in the absence of a detectable VN antibody response. Additionally, rN1–69 ELISAs on sera with conflicting VN and rG_L ELISA confirmed 4/7 rG_L ELISA + results correctly. One feature of both the rG_L and rN ELISAs is their ability to detect ELISA + VN – samples, both post-vaccination and from amongst field samples submitted for diagnosis. This appears due to an increased sensitivity of the ELISAs over the VN test, which detects the sub-population of antibodies neutralising EAV from the total pool of equine antibodies reactive to viral proteins. At the current time the rG_L 55–98 and rN1–69 ELISAs appear suitable for pre-screening samples prior to performing a confirmatory VN test on ELISA + samples. This could immediately accelerate both the clearing of horses with an EAV –, and reporting of horses with an EAV +, antibody status. Only more widespread use of these antigens in ELISA will confirm their suitability as stand-alone diagnostic reagents, or as replacements for the VN test.

Acknowledgements

This work was funded by the Animal Health Trust and in part by the Horserace Betting Levy Board (Project 617). The use of N as a diagnostic antigen is covered by Patent Application No. GB9512464-0.
References

Balasuriya, U.B.R., Rossitto, P.V., DeMaula, C.D. and MacLachlan, N.J. (1993) A 29K envelope glycoprotein of equine arteritis virus expresses neutralisation determinants recognised by murine monoclonal antibodies. J. Gen. Virol. 74, 2525–2529.

Balasuriya, U.B.R., MacLachlan, N.J., de Vries, A.A.F., Rossitto, P.V. and Rottier, P.J.M. (1995) Identification of a neutralisation site in the major envelope glycoprotein (G_{1}) of equine arteritis virus. Virology 207, 518–527.

Cavanagh, D., Brien, D.A., Brinton, M., Enjuanes, L., Holmes, K.V., Horzinek, M.C., Lai, M.M.C., Laude, H., Plagemann, P.G.W. and Siddell, S. (1994) Revision of the taxonomy of the Coronavirus, Torovirus and Arterivirus genera. Arch. Virol. 135, 227–237.

Chirnside, E.D. (1992) Equine arteritis virus: an overview. Br. Vet. J. 148, 181–197.

Chirnside, E.D., Wearing, C.M., Binns, M.M. and Mumford, J.A. (1994) Comparison of M and N gene sequences distinguishes variation amongst equine arteritis virus isolates. J. Gen. Virol. 74, 1491–1497.

Chirnside, E.D., de Vries, A.A.F., Mumford, J.A. and Rottier, P.J.M. (1995a) Equine arteritis virus neutralising antibody in the horse is induced by a determinant on the large envelope glycoprotein (G_{1}). J. Gen. Virol. 76, 1989–1998.

Chirnside, E.D., Francis, P.M., de Vries, A.A.F., Sinclair, R. and Mumford, J.A. (1995b) Development and evaluation of an ELISA using recombinant fusion protein to detect the presence of host antibody to equine arteritis virus (EAV). J. Virol. Methods 54, 1–13.

Conzelmann, K.-K., Visser, N., van Woensel, P. and Thiel, H.-J. (1993) Molecular characterisation of porcine reproductive and respiratory syndrome virus, a member of the arterivirus group. Virology 193, 329–339.

De Vries, A.A.F. (1994) The molecular biology of equine arteritis virus. PhD thesis, The University of Utrecht.

De Vries, A.A.F., Chirnside, E.D., Bredenbeek, P., Gravestein, L.A., Horzinek, M.C. and Spaan, W.J.M. (1990) All subgenomic mRNAs of equine arteritis virus contain a common leader sequence. Nucl. Acids Res. 18, 3241–3247.

De Vries, A.A.F., Chirnside, E.D., Horzinek, M.C. and Rottier, P.J.M. (1992) The structural proteins of equine arteritis virus. J. Virol. 66, 6294–6303.

De Vries, A.A.F., Raamsman, M.J.B., van Dijk, H.A., Horzinek, M.C. and Rottier, P.J.M. (1995) The small envelope glycoprotein (G_{2}) of equine arteritis virus folds into three distinct monomers and a disulfide-linked dimer. J. Virol. 69, 3441–3448.

Den Boon, J.A., Snijder, E.J., Chirnside, E.D., de Vries, A.A.F., Horzinek, M.C. and Spaan, W.J.M. (1991) Equine arteritis virus is not a togavirus but belongs to the coronavirus-like superfamily. J. Virol. 65, 2910–2920.

Deregt, D., de Vries, A.A.F., Raamsman, M.J.B., Elmgren, L.D. and Rottier, P.J.M. (1994) Monoclonal antibodies to equine arteritis virus proteins identify the G_{1} protein as a target for virus neutralisation. J. Gen. Virol. 75, 2439–2444.

Doll, E.R., Knappberger, R.E. and Bryans, J.T. (1957) An outbreak of abortion caused by the equine arteritis virus. Cornell Vet. 47, 69–75.

Gibson, T.J. (1984) Studies on the Epstein-Barr virus genome. PhD thesis, University of Cambridge, England.

Gödeny, E.K., Chen, L., Kumar, N., Methven, S.L., Koonin, E.V. and Brinton, M.A. (1993) Complete genomic sequence and phylogenetic analysis of the lactate dehydrogenase-elevating virus (LDV). Virology 194, 585–596.

Golnik, W., Michalska, Z. and Michalak, T. (1981) Natural equine viral arteritis in foals. Schweiz. Arch. Tierheilkd. 123, 523–533.

Hyllseth, B. (1973) Structural proteins of equine arteritis virus. Arch. gesamte Virusforsch. 40, 177–188.

Iwashita, O. and Harasawa, R. (1987) Structural polypeptides of equine arteritis virus. Jpn. J. Vet. Sci. 49, 923–925.

Kuo, L., Chen, Z., Rowland, R.R.R., Faaberg, K.S. and Plagemann, P.G.W. (1992) Lactate dehydrogenase-elevating virus (LDV): subgenomic mRNAs, mRNA leader and comparison of 3′-terminal sequences of two LDV isolates. Virus Res. 23, 55–72.
McCollum, W.H., Doll, E.R. and Wilson, J.C. (1961) The recovery of virus from horses with experimental cases of equine arteritis using monolayer cell cultures of equine kidney. Am. J. Vet. Res. 23, 465–469.

Meulenberg, J.J.M., Huist, M.M., de Meijer, E.J., Moonen, P.L.J.M., van Besten, A., de Kuyver, E.P., Wensvoort, G. and Moorman, R.J.M. (1993a) Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV. Virology 192, 62–72.

Meulenberg, J.J.M., de Meijer, E.J. and Moorman, R.J.M. (1993b) Subgenomic RNAs of Lelystad virus contain a conserved leader-body junction sequence. J. Gen. Virol. 74, 1697–1701.

Murphy, F.A. (1980) Togavirus morphology and morphogenesis. In: R.W. Schlesinger (Ed.), The Togaviruses: Biology Structure and Replication. Academic Press, London, pp. 241–316.

Plagemann, P.G.W. and Moennig, V. (1992) Lactate dehydrogenase-elevating virus, equine arteritis virus and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses. Adv. Virus Res. 41, 99–192.

Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory, New York.

Senne, D.A., Pearson, J.E. and Carbrey, E.A. (1985) Equine viral arteritis: a standard procedure for the virus neutralisation test and comparison of results of a proficiency test performed at five laboratories. In: Proceedings of the 89th Annual Meeting of the United States Animal Health Association, Milwaukee, WI, 1985. pp. 29–34.

Smith, D.B. and Johnson, K.S. (1988) Single-step purification of polypeptides expressed in Escherichia coli as fusion proteins with glutathione-S-transferase. Gene 67, 31–40.

Timoney, P.J., McCollum, W.H., Roberts, A.W. and Murphy, T.W. (1986) Demonstration of the carrier state in naturally acquired equine arteritis virus infection in the stallion. Res. Vet. Sci. 41, 279–280.

Vaala, W.E., Hamir, A.N., Dubovi, E.J., Timoney, P.J. and Ruiz, B. (1992) Fatal, congenitally acquired infection with equine arteritis virus in a neonatal thoroughbred. Equine Vet. J. 24, 155–158.

Van Berlo, M.F., Rottier, P.J.M., Spaan, W.J.M. and Horzinek, M.C. (1986) Equine arteritis virus (EAV) induced polypeptide synthesis. J. Gen. Virol. 67, 1543–1549.

Zeegers, J.J.W., van der Zeijst, B.A.M. and Horzinek, M.C. (1976) The structural proteins of equine arteritis virus. Virology 73, 200–205.